RedHill Biopharma Files 6-K, Announces Medi-Cal Deal

TL;DR

RHBP filed a 6-K for a new deal with Medi-Cal, details to follow.

AI Summary

RedHill Biopharma Ltd. filed a Form 6-K on October 1, 2024, to report a press release regarding a deal with Medi-Cal. The filing does not contain specific financial figures or dates related to the deal itself, but serves as notification of the press release.

Why It Matters

This filing indicates RedHill Biopharma is making a new announcement regarding a partnership or agreement with Medi-Cal, which could impact its business operations and future strategies.

Risk Assessment

Risk Level: medium — The filing itself is routine, but the underlying deal with Medi-Cal could carry significant business and financial risks or rewards for RedHill Biopharma.

Key Numbers

• 001-35773 — SEC File Number (Identifies the company's filings with the SEC.)

Key Players & Entities

• RedHill Biopharma Ltd. (company) — Registrant
• Medi-Cal (company) — Partner in a deal
• 001-35773 (dollar_amount) — SEC File Number
• October 2024 (date) — Reporting period

FAQ

Key Financial Figures

• $0 — (CDL) with no prior authorization and a $0 copay – a major benefit for approximate

Filing Documents

• zk2432089.htm (6-K) — 49KB
• image00001.jpg (GRAPHIC) — 308KB
• 0001178913-24-003183.txt ( ) — 474KB

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. REDHILL BIOPHARMA LTD. (the "Registrant") Date: October 1, 2024 By: /s/ Dror Ben-Asher Name: Dror Ben-Asher Title: Chief Executive Officer 2 Press Release RedHill and Medi-Cal Deal Maintains Talicia Reimbursement Without Prior Authorization for 15 Million Californians Medi-Cal, California's Medicaid healthcare program, and RedHill have renewed their contract to maintain Talicia's first-line position on the Medi-Cal Fee-For-Service (FFS) Contract Drug List (CDL) with no prior authorization and a $0 copay – a major benefit for approximately fifteen million Californian Medi-Cal patients -- The renewed terms reflect both parties' ongoing commitment to improving patient access and outcomes , reinforcing Talicia's role as an essential treatment option, and follow the new American College of Gastroenterology (ACG) Clinical Guideline 1 for H. pylori infection, listing Talicia as an empirically prescribed first-line option -- Talicia's convenient all-in-one three-times daily (TID) formulation offers a simplified patient experience, supporting high rates of H. pylori eradication without the requirement of prior resistance testing, and continues to be the branded H. pylori therapy most prescribed by U.S. gastroenterologists 2 -- H. pylori infection affects approximately 35% of the U.S. adult population 3 and is classified by the World Health Organization (WHO) as a Group 1 carcinogen, being the strongest known risk factor for gastric cancer 4 and a major risk factor for peptic ulcer disease 5 RALEIGH, N.C. and TEL-AVIV, Israel, October 1, 2024, RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced the renewal of its contract with Medi-Cal, California's Medicaid healthcare

Forward Looking Statements

Forward Looking Statements This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 and may discuss investment opportunities, stock analysis, financial performance, investor relations, and market trends. Such statements may be preceded by the words "intends," "may," "will," "plans," "expects," "anticipates," "projects," "predicts," "estimates," "aims," "believes," "hopes," "potential" or similar words and include, among others, statements regarding the potential effects of Talicia in the treatment of Helicobacter pylori infection. Forward-looking statements are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company's control and cannot be predicted or quantified, and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation: market and other conditions; the Company's ability to maintain compliance with the Nasdaq Capital Market's listing requirements; the risk that the addition of new revenue generating products or out-licensing transactions will not occur; the risk that acceptance onto the RNCP Product Development Pipeline will not guarantee ongoing development or that any such development will not be completed or successful; the risk that the FDA does not agree with the Company's proposed development plans for opaganib for any indication; the risk that observations from preclinical studies are not indicative or predictive of results in clinical trials; the risk that the FDA pre-study requirements will not be met and/or that the Phase 3 study of RHB-107 in COVID-19 outpatients will not be approved to commence or if approved, will not be completed or, should that be the case, that we will not be successful in obtaining alternative non-dilutive development funding for RHB-107; the risk that RHB-10

View Full Filing

View this 6-K filing on SEC EDGAR